{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:45:22Z","timestamp":1791265522046,"version":"4.1.0"},"reference-count":30,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2003,1,1]]},"abstract":"<jats:p>Purpose: This phase II trial investigated the safety and efficacy of two doses of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, plus fluorouracil (FU)\/leucovorin (LV) versus FU\/LV alone in patients with metastatic colorectal cancer.<\/jats:p>\n                  <jats:p>\n                    Patients and Methods: One hundred four previously untreated patients with measurable metastatic colorectal cancer were randomly assigned to one of the following three treatment groups: 36 to FU (500 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    )\/LV (500 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) alone, 35 to FU\/LV + low-dose bevacizumab (5 mg\/kg every 2 weeks), and 33 to FU\/LV + high-dose bevacizumab (10 mg\/kg every 2 weeks). FU\/LV was given weekly for the first 6 weeks of each 8-week cycle.\n                  <\/jats:p>\n                  <jats:p>Results: Compared with the FU\/LV control arm, treatment with bevacizumab (at both dose levels) plus FU\/LV resulted in higher response rates (control arm, 17%, 95% confidence interval [CI], 7% to 34%; low-dose arm, 40%, 95% CI, 24% to 58%; high-dose arm, 24%, 95% CI, 12% to 43%), longer median time to disease progression (control arm, 5.2 months, 95% CI, 3.5 to 5.6 months; low-dose arm, 9.0 months, 95% CI, 5.8 to 10.9 months; high-dose arm, 7.2 months, 95% CI, 3.8 to 9.2 months), and longer median survival (control arm, 13.8 months; 95% CI, 9.1 to 23.0 months; low-dose arm, 21.5 months, 95% CI, 17.3 to undetermined; high-dose arm, 16.1 months; 95% CI, 11.0 to 20.7 months). After cross-over, two of 22 patients had a partial response to bevacizumab alone. Thrombosis was the most significant adverse event and was fatal in one patient. Hypertension, proteinuria, and epistaxis were other potential safety concerns.<\/jats:p>\n                  <jats:p>Conclusion: The encouraging results of this randomized trial support further study of bevacizumab 5 mg\/kg plus chemotherapy as first-line therapy for metastatic colorectal cancer.<\/jats:p>","DOI":"10.1200\/jco.2003.10.066","type":"journal-article","created":{"date-parts":[[2002,12,28]],"date-time":"2002-12-28T12:57:17Z","timestamp":1041080237000},"page":"60-65","source":"Crossref","is-referenced-by-count":1328,"title":["Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)\/Leucovorin (LV) With FU\/LV Alone in Patients With Metastatic Colorectal Cancer"],"prefix":"10.1200","volume":"21","author":[{"given":"Fairooz","family":"Kabbinavar","sequence":"first","affiliation":[{"name":"From the Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, Hematology\/Oncology Clinic, Kaiser Permanente, Vallejo, Genentech Inc, South San Francisco, and Division of Hematology\/Oncology, University of California San Francisco, San Francisco, CA; Division of Hematology and Oncology, Duke University, Durham, NC; and Divisions of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert I.","family":"Hurwitz","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, Hematology\/Oncology Clinic, Kaiser Permanente, Vallejo, Genentech Inc, South San Francisco, and Division of Hematology\/Oncology, University of California San Francisco, San Francisco, CA; Division of Hematology and Oncology, Duke University, Durham, NC; and Divisions of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Fehrenbacher","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, Hematology\/Oncology Clinic, Kaiser Permanente, Vallejo, Genentech Inc, South San Francisco, and Division of Hematology\/Oncology, University of California San Francisco, San Francisco, CA; Division of Hematology and Oncology, Duke University, Durham, NC; and Divisions of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal J.","family":"Meropol","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, Hematology\/Oncology Clinic, Kaiser Permanente, Vallejo, Genentech Inc, South San Francisco, and Division of Hematology\/Oncology, University of California San Francisco, San Francisco, CA; Division of Hematology and Oncology, Duke University, Durham, NC; and Divisions of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Novotny","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, Hematology\/Oncology Clinic, Kaiser Permanente, Vallejo, Genentech Inc, South San Francisco, and Division of Hematology\/Oncology, University of California San Francisco, San Francisco, CA; Division of Hematology and Oncology, Duke University, Durham, NC; and Divisions of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazyna","family":"Lieberman","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, Hematology\/Oncology Clinic, Kaiser Permanente, Vallejo, Genentech Inc, South San Francisco, and Division of Hematology\/Oncology, University of California San Francisco, San Francisco, CA; Division of Hematology and Oncology, Duke University, Durham, NC; and Divisions of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Griffing","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, Hematology\/Oncology Clinic, Kaiser Permanente, Vallejo, Genentech Inc, South San Francisco, and Division of Hematology\/Oncology, University of California San Francisco, San Francisco, CA; Division of Hematology and Oncology, Duke University, Durham, NC; and Divisions of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Bergsland","sequence":"additional","affiliation":[{"name":"From the Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, Hematology\/Oncology Clinic, Kaiser Permanente, Vallejo, Genentech Inc, South San Francisco, and Division of Hematology\/Oncology, University of California San Francisco, San Francisco, CA; Division of Hematology and Oncology, Duke University, Durham, NC; and Divisions of Medical Science and Population Science, Fox Chase Cancer Center, Philadelphia, PA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199512000-00002"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<226::AID-CNCR6>3.0.CO;2-J"},{"key":"R4","unstructured":"Tanigawa N, Amaya H, Matsumura M, et al: Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 57:1043,1997\u20131046,"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1722::AID-CNCR46>3.0.CO;2-Z"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1159\/000011915"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9098(199812)69:4<230::AID-JSO7>3.0.CO;2-Q"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Abdalla SA, Behzad F, Bsharah S, et al: Prognostic relevance of microvessel density in colorectal tumours. Oncol Rep 6:839,1999\u2013842,","DOI":"10.3892\/or.6.4.839"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199101033240101"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/84.24.1875"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.18.1.0287"},{"key":"R12","unstructured":"Takahashi Y, Kitadai Y, Bucana CD, et al: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55:3964,1995\u20133968,"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.1997.01430290087018"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117857"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1016\/S1055-3207(18)30378-8"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.164"},{"key":"R17","unstructured":"Borgstr\u00f6m P, Gold DP, Hillan KJ, et al: Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19:4203,1999\u20134214,"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.843"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.851"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.10.1419"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800720909"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(82)90032-7"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(75)90055-7"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.1.113"},{"key":"R26","unstructured":"Lee C-G, Heijn M, di Tomaso E, et al: Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565,2000\u20135570,"},{"key":"R27","unstructured":"Gerber H-P, Kowalski J, Sherman D, et al: Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 60:6253,2000\u20136258,"},{"key":"R28","unstructured":"DeVore R, Fehrenbacher L, Herbst RS, et al: A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial growth factor) plus carboplatin\/paclitaxel (CP) to CP alone in patients with Stage IIIB\/IV NSCLC. Proc Am Soc Clin Oncol 19:485a,2000,  (abstr 1896)"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1657515"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200009283431302"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02034-1"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2003.10.066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T16:22:49Z","timestamp":1653495769000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2003.10.066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1,1]]}},"alternative-id":["10.1200\/JCO.2003.10.066"],"URL":"https:\/\/doi.org\/10.1200\/jco.2003.10.066","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1,1]]}}}